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doi:10.1016/j.ejvs.2009.08.004Abstract Two-stage autogenous brachial veinebrachial artery access (ABBA) has been
proposed as an option where adequate superficial vein is not available for the creation of
conventional haemodialysis fistulae.
Methods: This report depicts the clinical outcome of a series of 17 consecutive patients who
underwent ABBA in a single centre. Of the 17 patients, nine had had at least one previous
arterioventricular (AV) fistula or graft, and eight were new to haemodialysis. Patencies were
assessed using the KaplaneMeier survival analysis.
Results: In 14 patients, the brachial vein was transposed (82%) and the time to transposition
ranged from 4 to 26 weeks (median time: 6 weeks). The functional patency rate was 45.75%
at 12 months. After stage one, all fistulas that went on to develop well had a brachial vein flow
of at least 900 ml min1, and this was significantly higher than in fistulas that failed to develop
(pZ 0.005). The maturation rate in our study was 65% and the median time to cannulation of
the fistula was 8 weeks from the stage 1. Of the 17 patients, 12 (71%) experienced at least one
complication. Ten (59%) demonstrated moderate-to-severe stenoses; eight of which necessi-
tated angioplasty and/or percutaneous mechanical thrombolysis.
Conclusions: ABBA was characterised by a high incidence of complications and a long period to
achieve maturation. Despite close monitoring and a high rate of secondary interventions, the
patency rate was low. With this experience, we now only consider it an alternative in patients
without adequate superficial veins, who have had failed grafts or where there is a very high risk
of infection.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.44 2032993519; fax: þ44
doctors.org.uk (D. Valenti).
ty for Vascular Surgery. PublisheThe Dialysis Outcome and Quality Initiative (DOQI) of the
National Kidney Foundation has outlined strategies for
vascular access insertion and management.1 This article
emphasises the use of autogenous access over prosthetic,
specifically recommending that a minimum of 50% of newlyd by Elsevier Ltd. All rights reserved.
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fistulae have demonstrated their superiority over synthetic
grafts and have been shown to have better patency rates,
fewer complications and are cheaper.2e7 In accordance
with these recommendations, the use of autogenous
brachial veinebrachial artery fistulae (ABBA) has been
proposed as a better option than the use of grafts in
patients who lack adequate superficial vein for conven-
tional fistulae.8e14
We report our experience with the use of ABBA vascular
access in a consecutive series of patients treated in a single
centre.
Methods
In all cases, the indication for selection of ABBA was an
absence of adequate superficial vein for the use of a more
conventional fistula. Our preoperative routine includes
ultrasound vein mapping and arterial assessment in our
vascular laboratory. The cephalic and basilic veins are
assessed for diameter, patency and wall thickening at the
forearm, the antecubital fossa and in the upper arm.
The deep veins are not routinely assessed. Patients who lack
adequate superficial veins for conventional access (diameter
<2.0 mm) are considered for two-stage ABBA procedures.
Technique
We use a two-stage procedure that has been described
previously.8 The first stage constitutes the creation of an
anastomosis between the brachial artery and vein. Once
the vein is considered mature, it is transposed and super-
ficialised at a second operation.
We routinely use local rather than general anaesthetic
for the first-stage procedure, and longitudinal rather than
transverse or other incisions. The brachial artery and vein
are dissected and controlled. Where multiple veins exist,
the largest of these is used for arterioevenous anasto-
mosis. The selected vein is ligated and divided and
the proximal segment used for the fistula. Side-to-end
arterioevenous anastomoses are created under magnifica-
tion, using 7/0 polypropylene sutures.
The ABBA fistulae are assessed for suitability for trans-
position 6 weeks after the first-stage procedure according
to ultrasonic criteria. The criteria used are vein size >3.5
and fistula flow >600 ml min1. The second-stage proce-
dure is performed under general anaesthesia. It involves
a long medial upper arm incision, and full mobilisation of
the matured brachial vein from antecubital fossa to axilla
with ligation and division of all venous tributaries. There-
after, the brachial vein is divided close to the stage I
arterioevenous anastomosis, transposed subcutaneously
(lateral to the incision) and finally re-anastomosed to
a more proximal segment of brachial artery. We make
routine use of suction wound drains for this procedure.
The brachial veins flank the brachial artery, as venae
comitantes and near the lower margin of subscapularis they
join the axillary vein.15 They have numerous anastomoses
with each other and the superficial veins and their anatomy
may be quite variable. A low basilic vein confluence is not
uncommon, while the medial brachial vein often joins thebasilic vein before it becomes the axillary.15 In such cases,
a combined brachialebasilic vein is encountered during the
second-stage procedure.16 In an effort to minimise con-
founding variables, only plain brachial vein transpositions
were included.
All patients are entered into an intensive ultrasonic
fistula surveillance programme. Scans are performed at 2
and 4 weeks after stage 1 and 2 weeks after stage 2. The
fistula is then used once our standard ultrasound matura-
tion criteria are achieved. More assessments are scheduled
thereafter, depending on adequacy of dialysis and presence
of complications.
The brachial artery volume flow was automatically
calculated in accordance with what has been previously
reported by Martin et al.17 Volume (ml min1)Z A
(cm2) TA mean (cm s1) 60 s [AZmeasured cross-
sectional area (cm2), TAZmean time averaged mean
velocity (average of intensity weighted mean velocity)].
The brachial vein measurements were all in the first 10 cm
above the elbow crease and after having the subclavian
vein assessed to exclude central stenosis.
All data were prospectively gathered using a purpose-
designed database, and then analysed retrospectively. An
intent-to-treat analysis was employed such that no patients
were excluded from the analysis.
Statistics
Primary, assisted primary and functional patencies were
assessed using the KaplaneMeier survival analysis. The
ManneWhitney U test and the Wilcoxon signed-rank test
were used for comparisons of unpaired and paired contin-
uous variables, respectively. Differences were considered as
statistically significant if p< 0.05. Statistical analysis was
performed using SPSS 15.0. (SPSS Inc., Chicago, IL, USA).
Definitions
Primary, assisted primary and secondary patency are each
determined and defined in accordance with the previously
published standards for outcomes reports dealing with
arteriovenous haemodialysis (HD) accesses.18 The time to
cannulation of the fistula is defined as the time from stage 1
until the first cannulation for dialysis. An access was
defined as ‘functional’ when it was able to deliver a flow
rate of 350e400 mlmin1 without access recirculation to
maintain a treatment time less than 4 h, in accordance with
reported standards.18 Functional patency reflects the time
from the first successful cannulation until inability of the
access to provide adequate dialysis.
Early referral refers to referral for the establishment of
vascular access at least 3 months before the need for
dialysis or serum creatinine level <4 mg dl1.18
The DOQI criteria and complications are reported
according to the recommended standards for reports
dealing with AV haemodialysis access.18
Results
Between May 2007 and December 2008, 363 AV access
procedures were performed in our institution. Of these, 17
772 C. Lioupis et al.were electively scheduled for ABBA. In all such cases, the
specific indication for ABBA was an absence of adequate
superficial vein (vein diameter <2 mm) for the creation of
a more conventional fistula. Of these 17 patients, nine had
had at least one previous AV fistula or graft, while eight
were new to haemodialysis. From the later group, only one
was considered early referral while the other seven had
initiated dialysis using a tunnelled dialysis catheter.
The patient characteristics are shown in Table 1.
All ABBA procedures were performed by a single
consultant vascular surgeon with special interest in access
surgery and a considerable previous experience with the
ABBA procedure in this hospital, prior to commencing the
current protocol. In all the cases, the brachial veins were
easily identified at the antecubital fossa. During the
second-stage procedure, all the existing interconnections
with the basilic veins were interrupted and the brachial
veins were dissected up to the axilla. None of the combined
basilicebrachial vein was encountered.
Four of the 17 (23%) fistulae failed early. In two, the
fistula failed prior to transposition (stage 1 failures) and, in
two others, soon after transposition (stage 2 failures). The
apparent cause of early failure was a deep wound infection
in one; while in the other three cases the venae comitantes
(dominant brachial vein selected for use) were noted to be
small in calibre, with moderate-to-severe stenoses prox-
imal to the anastomosis at duplex follow-up. In 14 patients,
the brachial vein was transposed (82%) and the time to
transposition ranged from 4 to 26 weeks (median time:
6 weeks).Table 1 Demographic data.
Demographic data of 17 patients undergoing
brachio-brachial AV fistulae
Sex
Male, number 10 (59%)
Female, number 7 (41%)
Mean age (range) 59 (38e81)
Co-morbidities
Hypertension 12 (71%)
Diabetes Mellitus 9 (53%)
Ischaemic Heart Disease 6 (35%)
Peripheral Vascular Disease 6 (35%)
Cause of renal failure
Diabetes, number 8 (47%)
Hypertension, number 2 (12%)
Other, number 7 (41%)
Side
Right, number 4 (24%)
Left, number 13 (76%)
On Hemodialysis prior to AV access
Yes, number 16 (94%)
No, number 1 (6%)
Previous AV fistula or graft
Yes, number 9 (53%)
No, number 8 (47%)
Early referral
Yes, number 1 (6%)
No, number 16 (94%)Using estimates from the KaplaneMeier survival table at
12 months, the primary patency rate was 35.3% (standard
error (SE)Z 11.6%), while the assisted primary patency was
46.3% (SEZ 12.3%) (Figs. 1 and 2). A total of 11 (65%)
patients used the fistulae for dialysis at least once
successfully. The time to cannulation of the fistula ranged
from 6 to 52 weeks (median time: 8 weeks). The functional
patency was 45.75% (SEZ 12.35%) (Fig. 3).
Of the 17 patients, 12 (71%) experienced at least one
operative complication. These included thrombosis (nZ 6),
haematoma (nZ 3), discrete forearm oedema (nZ 3),
lymphorrhoea (nZ 2), wound infection (nZ 1) and aneu-
rysmal dilation (nZ 1). One patient developed mild steal
syndrome presenting with finger coldness, numbness pain
and discolouration. Two patients died during follow-up
from non-access-related causes, one of them before the
second-stage procedure of vein transposition could be
accomplished.
In addition, 10 (59%) developed moderate-to-severe
stenoses as identified using Duplex ultrasound. These were
sited at the anastomosis or in the proximal vein. Six were
identified and treated prior to fistula thrombosis, using
percutaneous angioplasty. Two further cases required
mechanical percutaneous thrombectomy and balloon
angioplasty to manage acute thrombotic fistula occlusions.
Two stenoses were not treated; one in the patient who died
after the stage 2 and one in the patient with the deep
wound infection.
Brachial vein diameter and blood flow, assessed 2 weeks
after the first and then the second stages of the procedure,
are shown in Table 2. After stage 1, all fistulas thatwent on to
develop well had a brachial vein flow of at least
900 ml min1, and thiswas significantly higher than in fistulas
that failed (pZ 0.005, ManneWhitney U test) (Fig. 4).
Similarly, the diameter of brachial vein in all fistulas that
went on to develop well was at least 4 mm after stage 1, but
the differencewith the fistulas that failed to developwas not
significant (pZ 0.237, ManneWhitney U test) (Fig. 5). Liga-
tion and division of venous side branches during stage 2 didFigure 1 One year primary patency. KaplaneMeier survival
table.
Figure 2 One year assisted primary patency. KaplaneMeier
survival table.
Figure 4 Brachial vein blood flow measurements (mls/min)
two weeks following the first stage of the procedure (1) and
two weeks following the second stage-transpostion e proce-
dure (2).
Autogenous BrachialeBrachial Fistula 773not result in a significant further increase in vein diameter or
flow rate (pZ 0.416 and pZ 0.305, respectively, Wilcoxon
signed-rank test).
Discussion
There can be little doubt that, for most patients, haemo-
dialysis access techniques using vein (fistulae) are more
satisfactory than prosthetic grafts. Nevertheless, there is
a significant minority in whom the superficial arm veins are
absent or inadequate for this purpose. Given the drive for
the use of autologous access, we have explored the use of
brachio-brachial fistulae (ABBA) in the management of this
problematic group. Our initial assumption was that the
technique would prove at least comparable to prosthetic
grafts, and that a superior patency rate would offset the
inconvenience of a two-stage technique with an obligatory
use of general anaesthetic.Figure 3 One year functional patency. KaplaneMeier
survival table.Many of our patients were elderly, had significant
co-morbidities and had limited options for vascular access.
Sixteen of seventeen had been started on haemodialysis
prior to AV access (late referrals) and the majority had had
at least one previous failed AV fistula or graft.
Although this series is small and, therefore, there are
limitations to the value of actuarial analysis, the calculated
primary, assisted primary and functional patencies at 1 year
(35.3%, 46.3% and 45.7%, respectively) are broadly in
accordance with those reported by Greenberg et al.19 and
Casey et al.10 These are the largest series published to
date, reporting series of 42 patients (50% primary patency
at 1 year) and 17 patients (40% patency at 1 year). In
smaller studies, Torina et al. have reported even lower
patency rates (24% primary patency and 45% assisted
primary patency at 12 months, in a series of 13 patients
following one-stage ABBA).14 By contradistinction, three
other studies have presented more encouraging results.
Dorobantu et al. reported an overall patency of 85% at
2 years in 33 patients that underwent ABBA in two stages11;
and Elwakeel et al. reported a cumulative primary patency
rate of 76% at 1 year and 55% at 2 years in a series of 21
patients that underwent ABBA in two stages.12 Similarly,
Srinivasaiah et al. have reported an over 60% patency
during a 10-month period.13Figure 5 Brachial vein diameter measurements (mm) two
weeks following the first stage of the procedure (1) and two
weeks following the second stage-transpostione procedure (2).
Table 2 Brachial vein blood flow (mls/min) and diameter (mm) measurements two weeks following the first stage and then
two weeks following the second-stage procedure.
Number of
case
Flow
(ml/min), 2 weeks
after 1st stage
Flow (ml/min),
2 weeks after
2nd stage
Brachial vein
diameter (mm),
2 weeks after 1st stage
Brachial vein
diameter (mm),
2 weeks after 2nd stage
Outcome
1 1600 1500 6 8 Developed well
2 380 400 3.5 4 Early failure
3 1300 750 7 8 Developed well
4 500 650 3.5 5 Limited use
5 900 1500 7 4 Developed well
6 900 1000 5 5 Developed well
7 600 e 4 e Failed prior
to transposition
8 1200 e 7 e Died prior
to transposition
9 1200 2000 5 6 Developed well
10 1150 750 5 4.5 Developed well
11 300 400 4 4 Early failure
12 400 e 3.5 e Failed prior
to transposition
13 750 750 3 2.8 Limited use
14 1300 2000 4 5 Developed well
15 1800 300 4 5 Developed well
16 800 1500 6 7 Not used because of
deep infection
17 1000 1100 6 6 Limited use
774 C. Lioupis et al.We used postoperative (stage 1) duplex ultrasound to
assess brachial vein diameter and flow in an effort to
predict fistula patency and utility. In a previous report,
Martin et al. studied 15 consecutive patients who under-
went brachio-cephalic fistula formation.17 They found that
at 2 weeks from construction all fistulae that went on to
develop well had a cephalic vein flow above 400 mlmin1,
but 26% of their patients developed forearm/hand claudi-
cation on exercise or signs of distal ischaemia. In our study,
brachial vein flow assessment showed that fistulas that
went on to develop well had flow rates of more than
900 ml min1; nevertheless, access-related hand ischaemia
occurred in only one case (out of 17). This constitutes
a significant divergence from the findings of Martin et al.17
The difference may be attributable to the anatomical
differences between the two venous systems (superficial as
opposed to deep) and the small sample size of the studies.
We found a high proportion of our patients suffered from
operative complications. This is in accordance with a report
by Torina et al., whose experience included a 77% compli-
cation rate (nZ 13).14 Anastomotic or venous outflow
stenoses were identified in 10 patients (59%) and six fistulae
thrombosed (35%). It has previously been suggested that
the small diameter of the brachial veins, together with
their frequently delicate and irregular structure, make
them susceptible to injury during transposition and that this
may result in stenosis and thrombosis.14 Moreover, multiple
short and wide tributaries must be divided during super-
ficialisation, and this may also predispose to stenosis. Seven
patients (41%) required at least one interventional proce-
dure (angioplasty and/or percutaneous mechanical throm-
bectomy) to assist maturation, improve patency or manage
fistula occlusion. In addition to specific fistula-relatedconcerns, almost half of the patients included in this study
presented with wound haematomas, lymph leaks and
forearm oedema. The brachial veins are placed deep in the
arm, closely accompanying the brachial artery. We postu-
late that this is a consequence of the second stage
(vein transposition), which necessitates extended dissec-
tion along the vein and artery, thereby potentially causing
lymphatic vessel disruption as well as simply resulting in
more extensive tissue damage than is the case with
conventional fistulae or prosthetic grafts.
The fistula maturation rate in our study was 65% and the
median time to cannulation of the fistula was 8 weeks from
the stage 1 procedure. Casey et al. reported even more
disappointing maturation rates (maturation rate of 47% and
a mean time of maturation of 11.7 weeks). In their study
population, the maturation rate was significantly better for
basilic vein transpositions than brachial vein trans-
positions.10 The proportion of ABBA that can be used at an
initial stage is quite low. The majority of patients require
two procedures and only a minority of fistulae can be used
after one procedure.
In summary, the use of brachio-brachial fistulae was
characterised by low patency rates, a long maturation
period, a high incidence of complications and frequent
requirement for secondary interventions to preserve
patency. Notwithstanding the fact that these patients
represent a subgroup in whom fistula failure is to be
expected, we are disappointed by the outcome. On the
basis of these data, we do not currently favour the use of
brachialebrachial fistulae. We now use prosthetic grafts for
patients who lack superficial vein for conventional autolo-
gous haemodialysis access. While this strategy may prove to
have similar patency and revision rates and could be
Autogenous BrachialeBrachial Fistula 775accompanied by more infective complications, it at least
allows early dialysis in a group who appear to be charac-
terised by late referral. Previous reports regarding the
efficacy of prosthetic grafts suggest actuarial patency rates
of between 22% and 75% at 1 year and beyond.5,20e24
Specifically, proactive graft surveillance programmes
coupled with early endovascular revision have been repor-
ted to yield graft long-term patency rates that are
comparable to transposed brachio-basilic fistulae, again
with the advantage of the earlier use of grafts balanced
against the need for more frequent secondary interventions
and the risk of graft infection.25 Accordingly, initial
evidence suggests that AV grafts outperform brachio-
brachial fistulae.14 In our current practice, we still consider
brachial vein AVFs a good alternative only in patients
without adequate superficial veins, who have failed grafts
or where there is a very high risk of infection, such as after
removal of infected prosthesis, in agreement with what has
been previously reported by others.13 The body of the
evidence suggests that fistulae are the first line of choice
for haemodialysis access in HIV-seropositive patients and
patients with intravenous drug abuse and accordingly we
consider ABBA AVFs in these and other immunocompro-
mised patients.26e28
The main limitation of our study is the small sample size
that affects the power of the study. Multivariable regres-
sion analysis to assess the association between explanatory
variables and patency rates was not performed because of
the small sample size. Moreover, it would be interesting if
we had preoperative imaging of brachial veins to compare
the diameter and blood flow with the postoperative values.
Since publication of the DOQI guidelines, demographics
of vascular access indicate improvement; however, there
remain areas for continued advance in practice pattern and
uniformity.29 Authors of several articles have proposed the
use of ABBA access in patients with absent superficial veins,
to avoid complications related to prosthetic grafts.
However, the current evidence does not support the
incorporation of ABBA into practice as the next step to
brachio-cephalic AVF and basilic vein transposition. Further
studies with prospective design and adequate power are
necessary to validate our results.Conflict of Interest
None.
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